[1] 王静,陶健,袁超.卵巢癌患者联合检测血清TK1、CA125 的临床价值[J].中华全科医学,2014,12(6):975-976. [2] Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer[J].Cancer Biomark,2011,9(1-6):287-305. [3] Moore RG, MacLanghlan S, Bast Rc Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer[J] Gynecol Oncol,2010,16(2):240-245. [4] 刘群结.CA125、CEA、HE4 与卵巢良恶性肿瘤的关系[J].实用癌症杂志,2015,30(4):482-484. [5] 张晓欲,宋志慧,李桂荣.肿瘤标志物在卵巢癌早期诊断中的研究进展[J].中国妇幼保健,2012,27(25):4002-4004. [6] Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer PrevRes(Phila), 2011,4:1356-1359. [7] 田满福.检测CA199、CA125、CA153及CEA在肿瘤诊断中的意义[J].临床实验医学杂志,2010,4(9) : 483 -485. [8] 周善良.血清HE4,CA125与TSGF联合检测在卵巢恶性肿瘤诊断中的价值[J].现代中西医结合杂志,2012,21(21):3500-3501. [9] 李杰,杜晓红,胡悦,等.血清3项肿瘤标志物联合检测在早期卵巢恶性肿瘤诊断中的应用[J].检验医学与临床,2013,10(4):445-447. [10] Moore RG, Jabore-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvicmess[J]. Am J Obstet Gynecol,2010,2013(3): 1-6. [11] 胡同秀,范社华,马媛.肿瘤标记物及凝血功能检测在卵巢癌鉴别诊断中意义[J].中华实用诊断与治疗杂志,2010,24(11):1100-1101. |